You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
維亞生物(01873.HK)上半年淨利潤1.44億元 同比增長952.55%
格隆匯 08-29 18:20

格隆匯8月29日丨維亞生物(01873.HK)公吿,回顧2024年上半年,集團收入9.82億元,較去年同期降幅約為14.0%;淨利潤1.44億元,同比增長952.55%;母公司普通權益持有人應占每股盈利0.05人民幣元。

淨利潤大幅提升,主要得益於因可轉債的全額償還而帶來相關財務調整項的消除。全球生物醫藥行業投融資數據逐步企穩,新藥研發企業的管線推進及研發投入亦逐步好轉,但傳導至CRO的行業性全面復甦仍需一定的時間。就中短期而言,雖外部宏觀環境的不確定性無可避免地會對大多CRO造成業績波動的影響。但從更長期的發展視角來看,國際生物醫藥的原創性開發依然保持穩健的增長態勢,研發和外包生產比例的持續提升依然是未來的主要趨勢。本集團以創新藥研發為基礎的CRO和CDMO業務,立足創新,深入整合資源,持續為客户提供從早期基於結構的藥物研發到商業化藥物生產的一站式綜合服務。

此外,自2023年集團完成了對戰略投資人淡馬錫、弘暉基金、淡明資本及迪拜投資公司的整體性引進工作後,戰略投資人目前正在對維亞集團的公司治理、業務運營、投融資規劃及戰略發展發揮協同效應。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account